4 assets in Testicular Non-Seminomatous Germ Cell Tumor

Therapeutic assets addressing Testicular Non-Seminomatous Germ Cell Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Testicular Non-Seminomatous Germ Cell Tumor	Jennifer King	P2	CCC (53)
Etoposide Testicular Non-Seminomatous Germ Cell Tumor	Nabil Adra	P2	CCC (53)
Ipilimumab Testicular Non-Seminomatous Germ Cell Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Testicular Non-Seminomatous Germ Cell Tumor	National Cancer Institute (NCI)	P2	CCC (53)